112 patents
Utility
Methods of administering solriamfetol to lactating women
16 Jan 24
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 24 May 23
Utility
Methods of administering solriamfetol to lactating women
16 Jan 24
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 24 May 23
Utility
Methods and compositions for treating excessive sleepiness
9 Jan 24
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
Lawrence Patrick Carter, Yuan Lu, Katayoun Zomorodi
Filed: 12 May 23
Utility
Pharmaceutical compositions comprising meloxicam
9 Jan 24
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 1 Nov 22
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
2 Jan 24
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 22 Jun 23
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
12 Dec 23
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 31 Mar 23
Utility
Methods of providing solriamfetol therapy to subjects with impaired renal function
12 Dec 23
The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function.
Katayoun Zomorodi
Filed: 31 Mar 23
Utility
Pharmaceutical compositions comprising meloxicam
28 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 7 Dec 22
Utility
Pharmaceutical compositions comprising meloxicam
28 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 29 Mar 23
Utility
Pharmaceutical compositions comprising meloxicam
7 Nov 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 2 Sep 22
Utility
Pharmaceutical compositions comprising meloxicam
31 Oct 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 2 Sep 22
Utility
Methods of administering solriamfetol to lactating women
24 Oct 23
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 1 Mar 23
Utility
Dosage forms and methods for enantiomerically enriched or pure bupropion
17 Oct 23
This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms.
Herriot Tabuteau
Filed: 10 Mar 22
Utility
Carbamoyl phenylalaninol compounds and uses thereof
10 Oct 23
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to treat disorders.
Fionn Hurley, Lawrence Patrick Carter
Filed: 9 Sep 21
Utility
Methods of administering solriamfetol to lactating women
10 Oct 23
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 1 Mar 23
Utility
Methods of administering solriamfetol to lactating women
3 Oct 23
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 30 Dec 22
Utility
Methods of administering solriamfetol to lactating women
3 Oct 23
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.
Herriot Tabuteau
Filed: 1 Mar 23
Utility
Pharmaceutical compositions comprising meloxicam
19 Sep 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 20 Sep 22
Utility
Treatment of cataplexy
1 Aug 23
The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Filed: 23 Jul 21
Utility
Pharmaceutical compositions comprising meloxicam
1 Aug 23
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.
Herriot Tabuteau
Filed: 7 Sep 22